XOMA (Nasdaq: XOMA) provided an update on its gevokizumab development program. Based on results from the Company's Phase 2 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE